Iterum Therapeutics plc - Ordinary Share (ITRM): Price and Financial Metrics
GET POWR RATINGS... FREE!
ITRM Stock Price Chart Interactive Chart >
ITRM Price/Volume Stats
| Current price | $1.32 | 52-week high | $7.49 |
| Prev. close | $1.33 | 52-week low | $1.21 |
| Day low | $1.28 | Volume | 30,731 |
| Day high | $1.36 | Avg. volume | 137,734 |
| 50-day MA | $1.64 | Dividend yield | N/A |
| 200-day MA | $3.44 | Market Cap | 16.15M |
Iterum Therapeutics plc - Ordinary Share (ITRM) Company Bio
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. Iterum Therapeutics plc was founded in 2015 and is based in Dublin, Ireland.
Latest ITRM News From Around the Web
Below are the latest news stories about ITERUM THERAPEUTICS PLC that investors may wish to consider to help them evaluate ITRM as an investment opportunity.
H.C. Wainwright Keeps Their Hold Rating on Iterum Therapeutics (ITRM)E ratio of -24.53.Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is negative on the stock. |
Iterum Therapeutics Reports Third Quarter 2022 Financial Results--Patient Enrollment in Registration Trial for uUTI Underway-- --Cash Runway into 2024-- DUBLIN, Ireland and CHICAGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the third quarter ended September 30, 2022. “We are thri |
Iterum Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results on November 10, 2022DUBLIN, Ireland and CHICAGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its third quarter 2022 financial results before the open of the U.S. financial markets on Thursday, November 10, 2022. Management wil |
H.C. Wainwright Remains a Hold on Iterum Therapeutics (ITRM)H.C. Wainwright analyst Ed Arce maintained a Hold rating on Iterum Therapeutics (ITRM - Research Report) on October 21. The company's shares closed yesterday at $1.82.According to TipRanks, Arce is a 4-star analyst with an average return of 7.3% and a 36.95% success rate. Arce covers the Healthcare sector, focusing on stocks such as Cidara Therapeutics, Mirum Pharmaceuticals, and Travere Therapeutics.Iterum Therapeutics has an analyst consensus of Hold.See Insiders’ Hot Stocks on TipRanks >> The company has a one-year high of $10.74 and a one-year low of $1.58. Currently, Iterum Therapeutics has an average volume of 92.13K. |
Iterum Announces First Patient Dosed in REASSURE, a Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections-- NDA resubmission expected in Second Half of 2024, if successful-- --Oral sulopenem, if approved, could be the first antibiotic approved for uncomplicated urinary tract infections in over 25 years-- DUBLIN, Ireland and CHICAGO, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company developing antibiotics to treat infections caused by multi-drug resistant pathogens, today announced that the first patient has been dosed in its P |
ITRM Price Returns
| 1-mo | -21.43% |
| 3-mo | -50.93% |
| 6-mo | -61.90% |
| 1-year | -81.96% |
| 3-year | -96.32% |
| 5-year | N/A |
| YTD | -77.54% |
| 2021 | -60.38% |
| 2020 | -78.02% |
| 2019 | -10.18% |
| 2018 | N/A |
| 2017 | N/A |
Continue Researching ITRM
Want to see what other sources are saying about Iterum Therapeutics plc's financials and stock price? Try the links below:Iterum Therapeutics plc (ITRM) Stock Price | Nasdaq
Iterum Therapeutics plc (ITRM) Stock Quote, History and News - Yahoo Finance
Iterum Therapeutics plc (ITRM) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...